Avineuro said that the results of the Phase I studies are expected to be available in May 2009.
Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-101 into Phase II clinical trials in the second quarter of 2009.
Avineuro said that the results of the Phase I studies are expected to be available in May 2009.
Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-101 into Phase II clinical trials in the second quarter of 2009.